{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T03:10:04Z","timestamp":1754017804763,"version":"3.41.2"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jval.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T20:58:33Z","timestamp":1714165113000},"page":"1012-1020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Dylan","family":"Maciel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven L.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Towle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devender","family":"Dhanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jval.2024.04.017_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2024.04.017_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"issue":"7-8","key":"10.1016\/j.jval.2024.04.017_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"14","key":"10.1016\/j.jval.2024.04.017_bib4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/sim.3594","article-title":"Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation","volume":"28","author":"Cooper","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2024.04.017_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-12-152","article-title":"Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes","volume":"12","author":"Jansen","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"29","key":"10.1016\/j.jval.2024.04.017_bib6","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1002\/sim.5470","article-title":"Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates","volume":"31","author":"Donegan","year":"2012","journal-title":"Stat Med"},{"issue":"20","key":"10.1016\/j.jval.2024.04.017_bib7","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/sim.6519","article-title":"Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatment","volume":"34","author":"Hong","year":"2015","journal-title":"Stat Med"},{"issue":"28","key":"10.1016\/j.jval.2024.04.017_bib8","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/sim.5442","article-title":"Mixed treatment comparisons using aggregate and individual participant level data","volume":"31","author":"Saramago","year":"2012","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jval.2024.04.017_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/sim.5584","article-title":"Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: individual patient data may be beneficial if only for a subset of trials","volume":"32","author":"Donegan","year":"2013","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jval.2024.04.017_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jrsm.1048","article-title":"Network meta-analysis of individual and aggregate level data","volume":"3","author":"Jansen","year":"2012","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.jval.2024.04.017_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo","year":"2020","journal-title":"J\u00a0R Stat Soc A"},{"issue":"30","key":"10.1016\/j.jval.2024.04.017_bib12","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo","year":"2020","journal-title":"Stat Med"},{"author":"Pandey","key":"10.1016\/j.jval.2024.04.017_bib13"},{"year":"2019","series-title":"Calibration of treatment effects in network meta-analysis using individual patient data","author":"Phillippo","key":"10.1016\/j.jval.2024.04.017_bib14"},{"issue":"5","key":"10.1016\/j.jval.2024.04.017_bib15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgab905","article-title":"An Indirect Treatment Comparison of semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression","volume":"107","author":"Lingvay","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jval.2024.04.017_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/0272989X221117162","article-title":"Validating the assumptions of population adjustment: application of multilevel network meta-regression to a network of treatments for plaque psoriasis","volume":"43","author":"Phillippo","year":"2023","journal-title":"Med Decis Mak"},{"issue":"2","key":"10.1016\/j.jval.2024.04.017_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.jval.2024.04.017_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"10.1016\/j.jval.2024.04.017_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jval.2023.07.001","article-title":"A\u00a0comparison of relative-efficacy estimate(s) derived from both matching-adjusted indirect comparisons and standard anchored indirect treatment comparisons: a review of matching-adjusted indirect comparisons","volume":"26","author":"Cassidy","year":"2023","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2024.04.017_bib20","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/sim.2370","article-title":"Improving ecological inference using individual-level data","volume":"25","author":"Jackson","year":"2006","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.jval.2024.04.017_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1467-985X.2007.00500.x","article-title":"Hierarchical related regression for combining aggregate and individual data in studies of socio-economic disease risk factors","volume":"171","author":"Jackson","year":"2008","journal-title":"Royal Statistical Society"},{"issue":"4","key":"10.1016\/j.jval.2024.04.017_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jrsm.1253","article-title":"Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models","volume":"8","author":"Freeman","year":"2017","journal-title":"Res Synth Methods"},{"issue":"15","key":"10.1016\/j.jval.2024.04.017_bib23","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2024.04.017_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"author":"Welton","key":"10.1016\/j.jval.2024.04.017_bib25"},{"issue":"9","key":"10.1016\/j.jval.2024.04.017_bib26","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2024.04.017_bib27","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncology"},{"issue":"8","key":"10.1016\/j.jval.2024.04.017_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"10.1016\/j.jval.2024.04.017_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jval.2024.04.017_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jval.2024.04.017_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jval.2024.04.017_bib38","article-title":"Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations","volume":"12","author":"Freitag","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.jval.2024.04.017_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A\u00a0process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope","year":"2014","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jval.2024.04.017_bib40","first-page":"245","article-title":"On the medians of gamma distributions and an equation of Ramanujan","volume":"121","author":"Choi","year":"1994"},{"key":"10.1016\/j.jval.2024.04.017_bib41","article-title":"Multinma: network meta-analysis of individual and aggregate data in Stan","author":"Phillippo","year":"2021","journal-title":"R Package Version 0.3.0"},{"year":"2018","series-title":"R: A Language and Environment for Statistical Computing","key":"10.1016\/j.jval.2024.04.017_bib42"},{"issue":"4","key":"10.1016\/j.jval.2024.04.017_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Stat Sci"},{"year":"2013","series-title":"Bayesian Data Analysis","author":"Gelman","key":"10.1016\/j.jval.2024.04.017_bib45"},{"key":"10.1016\/j.jval.2024.04.017_bib46","series-title":"Current Trends in Bayesian Methodology With Applications","first-page":"2","article-title":"Hamiltonian Monte Carlo for hierarchical models","author":"Betancourt","year":"2015"},{"issue":"6","key":"10.1016\/j.jval.2024.04.017_bib47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11222-013-9416-2","article-title":"Understanding predictive information criteria for Bayesian models","volume":"24","author":"Gelman","year":"2014","journal-title":"Stat Comput"},{"issue":"5","key":"10.1016\/j.jval.2024.04.017_bib48","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","article-title":"Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC","volume":"27","author":"Vehtari","year":"2017","journal-title":"Stat Comput"},{"key":"10.1016\/j.jval.2024.04.017_bib49","article-title":"Loo: Efficient Leave-One-Out Cross-Validation and WAIC for Bayesian Models","author":"Vehtari","year":"2022","journal-title":"R Package Version 2.5.1"},{"issue":"6","key":"10.1016\/j.jval.2024.04.017_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jval.2024.04.017_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/cer-2022-0045","article-title":"Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma","volume":"11","author":"Shah","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"suppl 1","key":"10.1016\/j.jval.2024.04.017_bib52","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood-2021-145321","volume":"138","author":"Rodr\u00edguez-Otero","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jval.2024.04.017_bib53","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1007\/s12325-021-01884-7","article-title":"DREAMM-2: indirect Comparisons of Belantamab Mafodotin vs. Selinexor+ dexamethasone and Standard of Care Treatments in Relapsed\/Refractory Multiple Myeloma","volume":"38","author":"Prawitz","year":"2021","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"10.1016\/j.jval.2024.04.017_bib54","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood-2019-124991","article-title":"Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the STORM and mammoth studies","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jval.2024.04.017_bib55","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/pst.2210","article-title":"Geometric approaches to assessing the numerical feasibility for conducting matching-adjusted indirect comparisons","volume":"21","author":"Glimm","year":"2022","journal-title":"Pharm Stat"},{"issue":"2","key":"10.1016\/j.jval.2024.04.017_bib56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jrsm.1608","article-title":"Network meta-interpolation: effect modification adjustment in network meta-analysis using subgroup analyses","volume":"14","author":"Harari","year":"2023","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.jval.2024.04.017_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-020-01198-2","article-title":"When does the use of individual patient data in network meta-analysis make a difference? A simulation study","volume":"21","author":"Kanters","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.jval.2024.04.017_bib58","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jrsm.1645","article-title":"Methodological considerations for novel approaches to covariate-adjusted indirect treatment comparisons","volume":"14","author":"Remiro-Az\u00f3car","year":"2023","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.jval.2024.04.017_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmjebm-2022-111931","article-title":"Using individual participant data to improve network meta-analysis projects","volume":"28","author":"Riley","year":"2023","journal-title":"BMJ Evid-Based Med"},{"author":"Remiro-Az\u00f3car","key":"10.1016\/j.jval.2024.04.017_bib60"},{"issue":"1","key":"10.1016\/j.jval.2024.04.017_bib61","first-page":"1","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jval.2024.04.017_bib62","article-title":"Current Practices for the Selection of Effect modifiers and Confounders in Population adjusted Indirect Comparisons (PAIC): a review of Technology Appraisals (TA)","author":"Chandler","year":"2023","journal-title":"Presented at ISPOR-EU"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524023490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T02:49:06Z","timestamp":1754016546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524023490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1098301524023490"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.017","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}